Targeting PIK3CB/YAP1 improves the sensitivity of paclitaxel by suppressing aging in head and neck squamous tumor cells
High PIK3CB expression in head and neck cancers is linked to poor prognosis and advanced tumor grades. PIK3CB promotes cell proliferation and reduces aging via the YAP1 pathway. The combination of navitoclax and paclitaxel reduces tumor cell proliferation and autonomous migration ability, providing a basis for further exploration of increasing chemotherapy sensitivity.
Authors
- Zheng Liang (ORCID: https://orcid.org/0000-0003-4532-4888)
- Ruopeng Sun (ORCID: https://orcid.org/0000-0003-0738-3721)
- Junzhi Liu (ORCID: https://orcid.org/0000-0002-7354-4207)
- Huimin Li (ORCID: https://orcid.org/0000-0001-8751-7501)
- Guoguang Ying (ORCID: https://orcid.org/0000-0002-7264-1224)
Institutions
- Tianjin Medical University General Hospital (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1186/s12935-025-03818-7
- Citations
- 1
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.05